Introduction
============

Lung cancer has the highest levels of morbidity and mortality of all malignant tumors globally, of which 80--85% patients are non-small cell lung cancer (NSCLC) ([@b1-ol-0-0-10364]). NSCLC includes squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. Compared with small cell carcinoma, NSCLC has a relatively slow growth rate and relatively late on-set of metastasis. Common symptoms of NSCLC include coughing, hemoptysis, chest pain, chest tightness and dyspnea. In recent years, radiotherapy has become the most common method for treating lung cancer and has an increasing role in treating patients with recurrent lung cancer who are unable to undergo surgery. Unlike small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC) is insensitive to radiotherapy and has a low response rate. Therefore, the overall therapeutic effect is unsatisfactory ([@b2-ol-0-0-10364],[@b3-ol-0-0-10364]). Therefore, knowing how to improve the therapeutic effect of radiotherapy is of great significance, and radiosensitization has become a major focus in the field of radiotherapy. Furthermore, researchers in and outside of China are currently searching and testing different methods of radiosensitization. Curcumin is a phenolic compound extracted from the rootstocks of multiple traditional Chinese medicines (TCMs), and multiple biological activities of curcumin have been reported, including antihypertensive and anti-hyperlipidemic effects, oxidation resistance and immunoregulation ([@b4-ol-0-0-10364]--[@b6-ol-0-0-10364]). In recent years, it has been reported that curcumin has multiple anti-tumor activities, including inhibiting proliferation and inducing cell apoptosis in tumors ([@b7-ol-0-0-10364]--[@b9-ol-0-0-10364]). Cisplatin is a common chemotherapeutic agent for lung cancer. A previous study has demonstrated that treatment with a combination of curcumin and cisplatin is able to inhibit proliferation and induce apoptosis in lung cancer ([@b10-ol-0-0-10364]). However, whether or not curcumin has a radiosensitization effect on NSCLC tumors is not clear, and to the best of our knowledge has not been demonstrated previously. Therefore, the present study was conducted to determine the radiosensitization effect of a combination of curcumin and cisplatin on the treatment of NSCLC A549 cells.

Materials and methods
=====================

### Key reagents and instruments

Curcumin and DMSO were purchased from Sigma-Aldrich, (Merck KGaA, Darmstadt, Germany). NSCLC A549 cells were purchased from the Chinese Academy of Sciences (Shanghai, China). Trypsin and RPMI-1640 medium were obtained from Gibco (Thermo Fisher Scientific, Inc., Waltham, MA, USA) and methyl thiazolyl tetrazolium (MTT) was purchased from Beyotime Institute of Biotechnology (Haimen, China). Rabbit anti-epidermal growth factor receptor (EGFR) polyclonal (1:1,000; cat. no. 1721100) and rabbit anti-GADPH (1:2,000; cat. no. 1721011) were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA), and newborn calf serum was purchased from Hangzhou Sijiqing Biological Engineering Materials Co., Ltd. (Hangzhou, China). The CO~2~ incubator with thermostat, medical linear accelerator, automatic enzyme standard instrument (ELX800; Omega Bio-Tek, Inc., Norcross, GA, USA), Hoefer mini-VE, ECL chemiluminescence reagent (PerkinElmer, Inc., Waltham, MA, USA), and nitrocellulose membranes (Omega Bio-Tek, Inc.) were also used.

### Cell culture

A549 cells were inoculated into RPMI-1640 medium containing 15% fetal bovine serum (FBS; Thermo Fisher Scientific, Inc.), and the cells were put into the incubator with a saturated humidity of 5% CO~2~ at 37°C. Adherent cells grew well and were sub-cultured every 3 days. The cells in the logarithmic phase were used for subsequent experiments.

### Irradiation conditions

An electron linear accelerator was used for irradiating cells in cell culture plates with a water tank below (height, 5 cm) and a tissue glue above (thickness, \~1.5 cm) the plates. The source-target distance was 100 cm, and 6MV--X ray irradiation was administered under a 10×10 cm irradiation field, with a 200 cGy/min dose rate. The cells were irradiated by different doses of X-ray (0--10 Gy) according to experimental requirements and then cultured in the incubator with a saturated humidity of 5% CO~2~ at 37°C for 24 h.

### MTT assay

The cells in the logarithmic phase were inoculated into 96-well culture plates at a concentration of 6.0×10^7^/l (100 µl/well) and cultured in a 5% CO~2~ incubator at 37°C for 24 h. Different doses of curcumin (10, 20, 50, 100 and 200 µmol/l) and cisplatin (1, 2, 5, 10 and 20 mg/l) were added to the culture plates following cell confluence. Cell cultures without curcumin or cisplatin were regarded as control groups, while the other cell cultures were the experimental groups. Following cultivation of the cells at 37°C for 24, 48 and 72 h, 20 µl MTT (2 g/l) was added to each well and cultured for another 4 h until cultivation was terminated. After the culture solution was removed, 150 µl DMSO was added to each well and shaken for 10 min. The absorbance value (ABS) of each well was determined by the microplate reader at a wavelength of 490 nm. A total of 6 parallel replicate wells were used for each concentration, and the experiment was repeated three times. The following formula was used to calculate cell viability: Cell viability=(ABS in experimental group/ABS in control group) ×100%.

### Colony formation experiment

According to the MTT results, concentrations of curcumin (10 µmol/l) and cisplatin (1 mg/l) with mild cytotoxicity were selected for subsequent experiments. Single-cell suspensions of A549 cells in the logarithmic phase were produced and inoculated into 24-well plates at 200 cells/well. Each plate included the following four groups: Single irradiation, curcumin + irradiation, cisplatin + irradiation, and curcumin + cisplatin + irradiation. After 24 h of transfection, the cells were irradiated by different doses of X-ray (0, 2, 4, 6, 8 and 10 Gy) for another 10 days of cultivation, fixed with absolute ethyl alcohol for 15 min and stained with 0.1% crystal violet for 20 min. The number of clones \>50 was counted under an inverted microscope in order to calculate the cloning efficiency (CE), as follows: CE (%)=(mean clone formation for the treatment group/inoculated cell number) ×100%. Surviving fraction (SF)=(CE in the irradiated group/CE in the non-irradiated group) ×100%. The experiments were repeated three times for calculating the average value.

According to the multi-target single-hit model \[SF=1-(1-e^−D/D0^)^N^\], a cell survival curve was drawn for calculating the sensitization enhancement ratio (SER). The equation for SER is as follows: SER=D~0~ in the control group/D~0~ in the experimental group. Based on the equation, D~0~ refers to the required dose of the curve index reduced by 63% (D~0~=1/k), and D~q~ refers to the threshold dose of cell damage (D~q~=D~0~.lnN). The experiment was repeated three times.

### Scratch wound assay

A549 cells in the four treatment groups were inoculated into 96-well plates at a density of 1×10^5^/ml and irradiated with 4 Gy X-ray. The cells formed into a cell monolayer. A line was drawn along the bottom of the culture plate using a pipette tip. The marginal area and relative distance of the scratch was captured and determined under an inverted microscope. After the culture solution was replaced with serum-free RPMI-1640 medium, the cells were cultured according to the requirements of the groups. Afterwards, an image of the area of the wounded region lacking cells was captured and calculated. Values of the area of the wounded region lacking cells prior to and following treatment were compared. The experiment was repeated three times.

### Matrigel assay for assessing invasion

A Matrigel assay was performed by using a Transwell chamber (Qiagen GmbH, Hilden, Germany) with pore size of 8.0 µm. The Transwell chamber was coated with 60 µl 0.8% liquid Matrigel at 37°C for incubation 4--5 h. A549 cells in the four treatment groups irradiated by 4 Gy X-ray were inoculated into RPMI-1640 medium containing 15% FBS, and the cells were placed into an incubator with a saturated humidity of 5% CO~2~ at 37°C for 24 h. They were then washed three times with Dulbecco\'s modified Eagle\'s medium (Thermo Fisher Scientific, Inc.) and suspended in culture medium containing 10% FBS (5×10^5^/ml). The cell suspension (200 ml) was added to the upper chamber of the Transwell chamber, and 600 ml culture medium containing 10% FBS was added into the lower chamber. Subsequently, the cells were cultured in a 5% CO~2~ incubator at 37°C for 24 h. The cells in the upper chamber were scrapped with a cotton swab then the culture medium containing 10% FBS was inverted, and dried at 37°C for 12 h. The cells were put in a 24-well plate, which were stained with 0.1% crystal violet (500 µl) were washed with phosphate buffer solution (PBS) following incubation at 37°C for 30 min. A total of four visual fields were observed with a confocal microscope (×63 oil immersed optics; DC 300F, Leica Microsystems GmbH, Wetzlar, Germany), and images for calculating the number of cells that migrated across the membranes. The experiment was repeated three times.

### Western blot analysis of signaling proteins

A549 cells in the four treatment groups irradiated with 4 Gy of X-rays and cultured for 24 h were added to RIPA lysis buffer (Hunan Sunshine Bio-Tech, Co., Ltd., Changsha, China) for 30 min and centrifuged at 12,000 r/min for 10 min at 37°C in a pre-cooled Eppendorf tube. The supernatant was collected for detection of protein concentration using Nanodrop 2000 spectrophotometer (Nanodrop Technologies; Thermo Fisher Scientific, Inc., Waltham, MA, USA). Then, an isopycnic loading buffer was re-added to the Eppendorf tube and bathed in boiling water for 5 min. Loading buffer (20--50 µl) was added. The proteins were separated by 12% SDS polyacrylamide gel electrophoresis, initially at 80 V and then at 100 V. The proteins were subsequently transferred into polyvinylidene difluoride membranes. Following incubation in 1% bovine serum albumin at room temperature for 2 h, the appropriate primary rabbit antibodies (1:500; cat no. SC-1616; Santa Cruz Biotechnology, Inc.) were added. The membranes were incubated with the primary antibodies at room temperature for 2 h and with the secondary antibody (cat no. SC-2054; Santa Cruz Biotechnology, Inc.) at room temperature for 1 h. The membrane was washed three times with Tris-buffered saline with Tween (TBST) for 5 min. The membranes were visualized with electrochemiluminescence (ECL; cat no. NCI4106; Thermo Fisher Scientific, Inc.) reagent. A single group was performed three times with X-film exposure, developed, and photographic fixed. GADPH was used as a loading control. The optical density of the target bands was detected using Image Pro Plus 6.0 software (Media Cybernetics, Inc., Rockville, MD, USA) and using the following equation: The final result=gray value of each band/internal reference.

### Statistical data analysis

SPSS (version 13.0; SPSS, Inc., Chicago, IL, USA) was used for data analysis. The data are expressed as the mean ± standard deviation. The differences between two groups were compared using a paired t-test, and the differences between multiple groups were compared using one-way analysis of variance with Tukey\'s test. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Inhibitory effect of curcumin on A549 NSCLC cells

As shown in [Fig. 1](#f1-ol-0-0-10364){ref-type="fig"}, the viability of A549 cells was significantly decreased (P=0.037) following treatment with different concentrations of curcumin or cisplatin for 24 h, and the inhibitory effect was dose and time-dependent. The IC~20~ values of curcumin and cisplatin on A549 cells were 15.74 µmol/l and 1.25 mg/l, respectively. To reduce the toxic effects of curcumin and cisplatin on A549 cells in the radiosensitization experiments, 10 µmol/l curcumin and 1 mg/l cisplatin were used.

### Inhibitory effect of X-ray irradiation on A549 cells following treatment with a combination of curcumin and cisplatin

Following treatment with curcumin, cisplatin, or a combination of curcumin and cisplatin for 24 h, A549 cells were irradiated with different doses of X-rays (0, 2, 4, 6, 8 and 10 Gy). It was demonstrated that SF value was lower in the curcumin + cisplatin + irradiation group compared with the other three treatment groups at 2\~10 Gy. The SF value was lower in the curcumin + cisplatin + irradiation group compared with the curcumin + irradiation group at 4--10 Gy. The SF value was lower in the cisplatin + irradiation group compared with the single irradiation group 2--10 Gy (P\<0.05; [Fig. 2](#f2-ol-0-0-10364){ref-type="fig"}). The SER values for the curcumin + irradiation, cisplatin + irradiation, and curcumin + cisplatin + irradiation groups were 1.24, 1.31 and 1.96, respectively ([Table I](#tI-ol-0-0-10364){ref-type="table"} and [Fig. 2](#f2-ol-0-0-10364){ref-type="fig"}).

### Inhibitory effects of X-ray irradiation on migration of A549 cells following treatment with a combination of curcumin and cisplatin

The migration ratios in the curcumin + irradiation, cisplatin + irradiation, and curcumin + cisplatin + irradiation groups were 86.0±9.0, 79.0±6.0, and 37.0±5.0%, respectively ([Fig. 3](#f3-ol-0-0-10364){ref-type="fig"}) compared with the single irradiation group (1.00) (P\<0.05; [Fig. 2](#f2-ol-0-0-10364){ref-type="fig"}).

### Inhibitory effects of X-ray irradiation on invasion of A549 cells following treatment with a combination of curcumin and cisplatin

The number cells invaded through the membrane in the single irradiation, curcumin + irradiation, cisplatin + irradiation, and curcumin + cisplatin + irradiation groups were 521±21, 352±17, 229±12, and 154±16, respectively (P\<0.05; [Fig. 4](#f4-ol-0-0-10364){ref-type="fig"}).

### Inhibitory effects of X-ray irradiation on the expression of EGFR following treatment with a combination of curcumin and cisplatin

The levels of EGFR in the curcumin + irradiation, cisplatin + irradiation, and curcumin + cisplatin + irradiation groups following treatment for 48 h were 0.47±0.04, 0.41±0.04 and 0.23±0.04, respectively, which were significantly lower compared with the single irradiation group (0.59±0.05; P\<0.05). The level of EGFR expression in the curcumin + cisplatin and irradiation group was lower compared with the curcumin + irradiation and cisplatin + irradiation groups (P\<0.05; [Fig. 5](#f5-ol-0-0-10364){ref-type="fig"}).

Discussion
==========

As the results of the present study demonstrated, treatment with curcumin was able to inhibit the viability of humanized NSCLC A549 cells, and that this inhibitory effect was concentration- and time-dependent, which was consistent with the results of previous studies ([@b9-ol-0-0-10364],[@b10-ol-0-0-10364]). In addition, curcumin has a notable inhibitory effect on other tumors including brain tumors ([@b11-ol-0-0-10364]), therefore indicating the broad anti-tumor effect of curcumin. In order to control the cytotoxicity of curcumin during radiotherapy ([@b12-ol-0-0-10364]), lower doses of curcumin that did not exhibit marked cytotoxicity were selected for subsequent experiments. The cell survival curve of the A549 cells revealed that the SF irradiation dose increased with an exponential-reducing manner, particularly in the dose range of 6--10 Gy and the cell survival curve which indicated that A549 cells may exhibit resistance to radiation and have the capacity to undergo DNA repair when exposed to sub-lethal damage.

The present study also indicated that treatment with curcumin or cisplatin may be able to promote A549 cells death following X-ray irradiation. It was demonstrated that the inhibitory effect of using a combination of curcumin and cisplatin was more effective compared with the treatment of curcumin or cisplatin alone. The SF value of curcumin + cisplatin + irradiation was lower (SER, 1.96) compared with that of irradiation and treatment with either curcumin (SER, 1.24) or cisplatin alone (SER, 1.31), which indicates a reduced resistance to radiation. Therefore, these findings indicate that treatment with a combination of curcumin and cisplatin was able to have an evident radiosensitization effect on A549 cells cultured *in vitro*.

Invasion and metastasis are the main causes of therapeutic failure in lung cancer ([@b13-ol-0-0-10364]), and radiotherapy is used for treating metastatic lesions of lung cancer. Therefore, the present study investigated the effects of curcumin + cisplatin treatment on A549 cells *in vitro* to evaluate the radiosensitization effects of curcumin + cisplatin. The results demonstrated that treatment with a combination of curcumin and cisplatin was able to increase the inhibitory effect of X-ray irradiation on the migration and invasion of A549 cells, which is marked by a reduced migration distance and a reduced number of invaded cells in the curcumin + cisplatin group, compared with the single irradiation group. These results indicate that treatment with curcumin + cisplatin was able to have an overall radiosensitization effect on A549 cells and therefore may be able to inhibit proliferation, invasion and metastasis of lung cancer cells.

In recent years, EGFR has been demonstrated to have an important role in mediating resistance to radiation in malignant tumors ([@b14-ol-0-0-10364],[@b15-ol-0-0-10364]), and an association between high EGFR expression and increased resistance of radiation has been revealed ([@b16-ol-0-0-10364]). The mechanism of EGFR-mediated radiation resistance is complex and may be associated with self-healing when tumor cells become damaged ([@b17-ol-0-0-10364]). Therefore, reducing the level of EGFR expression is a common mechanism of action for sensitizers.

The present study indicated that curcumin was able to increase the inhibitory effects of X-ray irradiation on the expression of EGFR, and the inhibitory effect was increased when cells were treated with a combination of curcumin and cisplatin, compared with the single irradiation group. In view of the signaling pathway associated with EGFR, further experiments with a combination of curcumin and cisplatin on the associated signaling pathway should be conducted.

In conclusion, treatment with a combination of curcumin and cisplatin was able to exert radiosensitization effects on A549 cells and was able to inhibit the A549 cell proliferation, and invasion and migration of the tumor. The mechanism of action of curcumin and cisplatin may be associated with the inhibition of EGFR-associated signaling pathways. Therefore, treatment with a combination of curcumin and cisplatin may have promising prospects in increasing the effects of radiotherapy on NSCLC.
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![Effects of different concentrations of (A) curcumin and (B) cisplatin on the viability of A549 cells.](ol-18-01-0529-g00){#f1-ol-0-0-10364}

![Cell survival curve based on the multi-target single-hit model. SF, surviving fraction. \*P\<0.05 vs. single irradiation group. ^\#^P\<0.05 vs. curcumin + irradiation group, ^&^P\<0.05 vs. cisplatin + irradiation group. ^\^^P\<0.05 vs. curcumin + irradiation + irradiation group.](ol-18-01-0529-g01){#f2-ol-0-0-10364}

![Migration assay of A549 cells in four treatment groups following 24 h. (A) Curcumin + cisplatin + irradiation; (B) cisplatin + irradiation group; (C) curcumin + irradiation group and (D) single irradiation group.](ol-18-01-0529-g02){#f3-ol-0-0-10364}

![Invasion assay of A549 cell in four treatment groups following 24 h. (A) Single irradiation group; (B) curcumin + irradiation group; (C) cisplatin + irradiation group and (D) curcumin + cisplatin + irradiation group. (E) Cell number in different groups after X-ray irradiation. Magnification, ×200. Differences between multiple groups were compared using one-way analysis of variance with Tukey\'s test. \*P\<0.05, \*\*P\<0.01 vs. single irradiation group.](ol-18-01-0529-g03){#f4-ol-0-0-10364}

![EGFR expression following 24 h. (A) Single irradiation group; (B) curcumin + irradiation group; (C) cisplatin + irradiation group and (D) curcumin + cisplatin +irradiation group. (E) Quantitative evaluation of EGFR level by western blotting after X-ray irradiation. Differences between multiple groups were compared using one-way analysis of variance with Tukey\'s test. \*P\<0.05, \*\*P\<0.01 vs. single irradiation group. EGFR, epidermal growth factor receptor.](ol-18-01-0529-g04){#f5-ol-0-0-10364}

###### 

Survival values (%) of A549 cells in four treatment groups irradiated by different doses of X-rays.

                                                    Radiation dose (Gy)                                                                                                                                                                                                                                                                                                                                                                                                                                      
  ------------------------------------------------- --------------------- -------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------
  Single irradiation, mean ± SD                     100.00±1.23           91.10±1.69                                                                                               70.22±1.33                                                                                               52.25±1.74                                                                                               41.58±2.28                                                                                              17.08±1.93
  Curcumin + irradiation, mean ± SD                 95.01±3.21            85.59±2.05                                                                                               56.35±1.91^[a](#tfn1-ol-0-0-10364){ref-type="table-fn"}^                                                 35.40±2.03^[a](#tfn1-ol-0-0-10364){ref-type="table-fn"}^                                                 19.04±1.53^[a](#tfn1-ol-0-0-10364){ref-type="table-fn"}^                                                9.61±2.24^[a](#tfn1-ol-0-0-10364){ref-type="table-fn"}^
  Cisplatin + irradiation, mean ± SD                97.82±2.04            80.78±1.75^[a](#tfn1-ol-0-0-10364){ref-type="table-fn"}^                                                 62.79±2.06^[a](#tfn1-ol-0-0-10364){ref-type="table-fn"},[b](#tfn2-ol-0-0-10364){ref-type="table-fn"}^    41.49±1.24^[a](#tfn1-ol-0-0-10364){ref-type="table-fn"},[b](#tfn2-ol-0-0-10364){ref-type="table-fn"}^    22.40±1.09^[a](#tfn1-ol-0-0-10364){ref-type="table-fn"},[b](#tfn2-ol-0-0-10364){ref-type="table-fn"}^   12.09±1.76^[a](#tfn1-ol-0-0-10364){ref-type="table-fn"},[b](#tfn2-ol-0-0-10364){ref-type="table-fn"}^
  Curcumin + cisplatin and irradiation, mean ± SD   96.54±2.55            72.78±2.64^[a](#tfn1-ol-0-0-10364){ref-type="table-fn"}--[c](#tfn3-ol-0-0-10364){ref-type="table-fn"}^   42.79±2.64^[a](#tfn1-ol-0-0-10364){ref-type="table-fn"}--[c](#tfn3-ol-0-0-10364){ref-type="table-fn"}^   22.49±1.83^[a](#tfn1-ol-0-0-10364){ref-type="table-fn"}--[c](#tfn3-ol-0-0-10364){ref-type="table-fn"}^   9.40±0.84^[a](#tfn1-ol-0-0-10364){ref-type="table-fn"}--[c](#tfn3-ol-0-0-10364){ref-type="table-fn"}^   2.22±2.02^[a](#tfn1-ol-0-0-10364){ref-type="table-fn"}--[c](#tfn3-ol-0-0-10364){ref-type="table-fn"}^

P\<0.05 vs. single irradiation group

P\<0.05 vs. curcumin + irradiation group

P\<0.05 vs. cisplatin + irradiation group. SD, standard deviation.
